Arcadia Biosciences Stock News

Arcadia Biosciences Inc (RKDA) shares closed 1.4% lower than its previous 52 week low, giving the company a market cap of $31M. The stock is currently down 44.3% year-to-date, down 57.6% over the past 12 months, and down 93.9% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 26.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Materials industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -5900.4% The company's stock price performance over the past 12 months lags the peer average by -522.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 17.2% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Wall Street brokerages forecast that Arcadia Biosciences, Inc. (NASDAQ:RKDA) will announce sales of $3.68 million for the current quarter, according to Zacks. Two analysts have provided estimates for Arcadia Biosciences earnings. The lowest sales estimate is $3.63 million and the highest is $3.72 million. Arcadia Biosciences reported sales of $7.13 million in the same quarter []

Arcadia Biosciences (NASDAQ:RKDA) posted its quarterly earnings results on Sunday. The basic materials company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters consensus estimate of ($0.23) by $0.13, Fidelity Earnings reports. Arcadia Biosciences had a negative return on equity of 44.75% and a net margin of 3.98%. During the same quarter []

Arcadia Biosciences (NASDAQ:RKDA) announced its quarterly earnings data on Sunday. The basic materials company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.13, Fidelity Earnings reports. Arcadia Biosciences had a negative return on equity of 44.75% and a net margin of 3.98%. During the same quarter last year, the company []

Arcadia Biosciences' (RKDA) CEO Matt Plavan on Q3 2021 Results - Earnings Call Transcript

Arcadia Biosciences (NASDAQ:RKDA) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.

Arcadia Biosciences, Inc said it has launched a national search for a new CEO as the company further expands into the consumer packaged goods (CPG) sector. Current CEO Matt Plavan will step down from

DAVIS, Calif., Sept. 7, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced that it has launched

Arcadia Biosciences reported a five-fold increase in revenue in its second quarter, mainly thanks to sales from the newly acquired portfolio of wellness brands, as well as its GoodHemp seed sales. For

Arcadia Biosciences' (RKDA) CEO Matt Plavan on Q2 2021 Results - Earnings Call Transcript